Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.

Shareholders might have noticed that Novartis AG ( VTX:NOVN ) filed its second-quarter result this time last week.

Synendos Therapeutics appoints Dr. George Garibaldi as CMO to enhance phase 2 clinical development of its lead drug asset SYT-510: Basel, Switzerland Saturday, July 19, 2025, 15:3 ...

In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer discussed what bank industry executives were saying about ...

AbbVie’s flagship Humira (adalimumab) is also approved in HS and was the first biologic to be approved in the indication in ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

ZoomRx surveyed 57 neurologists in the U.S. this month, revealing that no single drug brand holds more than 5% of top-of-mind ...

An Omnicom spokesperson confirmed that the 2025 MM+M Agency 100 honoree will soon be folded into Omnicom Health subsidiaries.

Sarepta Therapeutics shares plunge over 37% as FDA weighs halting shipments of its key gene therapy, Elevidys, after patient ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Despite a phase 3 flop, Bristol Myers Squibb—encouraged by “clinically meaningful results” and bruised by three other recent pivotal trial failures—still plans to discuss a potential approval filin | ...